Third, patients were followed
for 1 month after therapy was completed,
which is a strength in comparison with studies
lacking a documented follow-up visit but is also
a limitation. S. aureus infections are often recurrent,
29,30 and 1 month of follow-up may be inad- equate for assessing the efficacy of a drug in
preventing recurrent disease.